Development of evacetrapib to treat high-risk atherosclerotic CV disease is stopped- Eli Lilly
Eli Lilly and Company and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase III trial of the investigational medicine evacetrapib, due to insufficient efficacy. Lilly will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the programme.
The independent data monitoring committee based its recommendation on data from periodic data reviews, which suggested there was a low probability the study would achieve its primary endpoint based on results to date. The study is not being stopped for safety findings. After further analysis, results of the study will be presented in scientific forums in the future.